Literature DB >> 3866513

In vitro activity of CI-934, a quinolone carboxylic acid active against gram-positive and -negative bacteria.

M A Cohen, T J Griffin, P A Bien, C L Heifetz, J M Domagala.   

Abstract

CI-934 is a totally synthetic difluorinated quinolinecarboxylic acid with an ethyl-amino-methyl pyrrolidine side chain, which has broad-spectrum antibacterial activity, including particular potency directed against streptococci and staphylococci. The CI-934 MIC (micrograms per milliliter) for 90% of the strains tested was 0.4 (range, 0.2 to 0.8) for a group of streptococci (pneumococci, viridans streptococci, Streptococcus faecalis, and Lancefield groups A, B, and C), 0.2 (0.05 to 0.2) for staphylococci (including methicillin-resistant Staphylococcus aureus), 0.025 (less than or equal to 0.003 to 0.025) for Haemophilus influenzae and Neisseria gonorrhoeae, 1.6 (0.1 to 25) for Enterobacteriaceae, 25 (3.1 to 25) for Pseudomonas aeruginosa, and 1.6 (0.05 to 3.1) for non-Bacteroides anaerobe species. CI-934 was equally active in vitro against multi-drug-resistant and -sensitive isolates, and cross-resistance was not apparent. Potency increased with alkalinity and was somewhat lower in urine. CI-934 was bactericidal. Inhibitory activity was generally unaffected by anaerobiosis, light, changes in inoculum size or cation concentration, or addition of human serum or sodium cholate.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3866513      PMCID: PMC180325          DOI: 10.1128/AAC.28.6.766

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Broth-dilution method for determining the antibiotic susceptibility of anaerobic bacteria.

Authors:  D R Stalons; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1975-01       Impact factor: 5.191

2.  Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media.

Authors:  L B Reller; F D Schoenknecht; M A Kenny; J C Sherris
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

3.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

4.  Effect of the concentrations of magnesium and calcium on the in-vitro susceptibility of Pseudomonas aeruginosa to gentamicin.

Authors:  D N Gilbert; E Kutscher; P Ireland; J A Barnett; J P Sanford
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

5.  Comparison of microdilution and agar dilution procedures for testing antibiotic susceptibility of Neisseria gonorrhoeae.

Authors:  M A Shapiro; C L Heifetz; J C Sesnie
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

6.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

7.  Effects of membrane-energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: a model for entry of streptomycin and gentamicin in susceptible and resistant bacteria.

Authors:  L E Bryan; H M Van Den Elzen
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

  7 in total
  10 in total

1.  In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents.

Authors:  N Manek; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Rate of bactericidal activity for Streptococcus faecalis of a new quinolone, CI-934, compared with that of amoxicillin.

Authors:  E Yourassowsky; M P Van der Linden; M J Lismont; F Crokaert; Y Glupczynski
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

3.  Code names for new compounds.

Authors:  S M Ringel
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

4.  In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains.

Authors:  R P Smith; A L Baltch; M C Hammer; J V Conroy
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.

Authors:  T E Renau; J W Gage; J A Dever; G E Roland; E T Joannides; M A Shapiro; J P Sanchez; S J Gracheck; J M Domagala; M R Jacobs; R C Reynolds
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.

Authors:  V Korten; J F Tomayko; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  Identification of Streptococcus faecalis and Streptococcus faecium and susceptibility studies with newly developed antimicrobial agents.

Authors:  M J Kim; M Weiser; S Gottschall; E L Randall
Journal:  J Clin Microbiol       Date:  1987-05       Impact factor: 5.948

8.  Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.

Authors:  A G Miranda; A R Wanger; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

9.  In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy.

Authors:  D F Sahm; G T Koburov
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

10.  In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents.

Authors:  W Mandell; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.